Canadian Consortium on Neurodegeneration in Aging (CCNA)
The Canadian Consortium on Neurodegeneration in Aging (CCNA) is the premier research hub for all aspects of research involving neurodegenerative diseases that affect cognition in aging – including Alzheimer's disease. Initially funded in 2014, the CCNA was renewed into its second phase in April 2019. The CCNA is funded by CIHR and many partners (see below). Dr. Howard Chertkow leads CCNA and is supported by an extended team of researchers across Canada.
What is the CCNA?
The initial vision of the CCNA was to bring together the best of Canadian research in the field of neurodegenerative diseases affecting cognition in a collaborative and synergistic space. The CCNA has grown to be a large cohesive research enterprise that has created new synergies among the Canadian research community and is catalyzing new and exciting research. Researchers are continuing to work on bold and transformative research ideas to make a difference in the quality of life and the quality of services for those living with the effects of neurodegenerative diseases affecting cognition and their caregivers. Composed of 350+ researchers, the CCNA is continuously evolving and welcome additional new researchers through an application for membership process.
The CCNA includes research in Alzheimer's disease, Vascular dementia, Frontotemporal dementia, and Lewy body dementia as well as other forms of dementia. The CCNA is promoting high impact, inter-institutional and interdisciplinary collaborations through a Pan-Canadian approach, while also supporting the deployment of unique research platforms allowing for interdisciplinary research on brain diseases causing dementia. The CCNA also includes a number of cross-cutting components including capacity building, knowledge transfer program, ethics and a unique one on women, gender, sex and dementia.
Goals and objectives
The goal of the CCNA is to support a collaborative, integrated, strategically oriented, bold, transformative and highly impactful Canadian Consortium on Alzheimer's and other neurodegenerative diseases in aging having an impact on cognition, in order to reach these objectives:
- Increasing the interdisciplinary collaborations within and across Teams, Themes and Cross-Cutting Components in the area of age-related neurodegenerative diseases having an impact on cognition, including but not limited to prevention and risk reduction, diagnosis, treatment, care, services, social aspects;
- Increasing capacity building in the areas of age-related neurodegenerative diseases that have an impact on cognition, including but not limited to prevention and risk reduction, diagnosis, treatment, care, services, social aspects, while integrating sex and gender considerations, Indigenous health perspectives (i.e., First Nations, Inuit and Métis), and persons with lived experience;
- Enhancing Canadian researchers’ competitiveness, international presence, and influence on outcomes related to neurodegenerative diseases affecting cognition.
Partner were initially engaged at the CCNA Partners’ Forum. CCNA partners have played a pivotal role in shaping and developing this initiative. They will continue to contribute to its success as it moves forward. Partners will help put Canada at the forefront of research activities, which will lead to improved health, and quality of life of Canadians affected by these diseases.
We would like to thank our partners for their generous support and involvement in this exciting opportunity.
Current Phase 2 Partners
Phase 1 Partners
Interested in partnering?
Partners are welcomed to contribute to increase the relevancy and the impact of the research efforts required to face neurodegenerative diseases like Alzheimer's disease and other neurodegenerative diseases causing dementia. Partners representing end users and/or wishing to contribute to the research are invited to contact us.
Toll Free: 1-888-603-4178
- Date modified: